drugset / Trial / NCT00566098
Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma
Phase 1/2
Completed
26 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Activating white blood cells in the laboratory may help them kill more cancer cells when they are put back in the body. This may be an effective treatment for patients undergoing a stem cell transplant for multiple myeloma. PURPOSE: This phase I/II trial is studying the side effects of activated white blood cells and to see how well they work in treating patients who are undergoing a stem cell transplant for newly diagnosed stage II or stage III multiple myeloma.
Timeline
- Start
- 2007-11
- Primary completion
- 2014-06
- Completion
- 2018-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MILs | Cell therapy | — | — |
| Subject | Prevnar 13 | Vaccine | — | — |
| Background | Melphalan | Small molecule | 100 mg/m2 | Intravenous |